Cytokinetics Financials - Benzinga

Cytokinetics Inc

CYTKNASDAQ

Trade with Public

Trade with Public

$72.09

-5.81-7.46%

At close: Aug 28, 5:00 PM EST

$73.00

0.911.26%

After Hours: Aug 28, 5:41 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Cytokinetics Financials

Cytokinetics (CYTK) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cytokinetics Q2 EPS $(1.50) Beats $(1.63) Estimate, Sales $28.624M Beat $17.382M Estimate

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.63) by 7.98 percent. This is a 33.93 percent decrease over losses of $(1.12) per share from the

Benzinga Newsdesk

PRO
Cytokinetics Q1 EPS $(1.67) Misses $(1.64) Estimate, Sales $19.355M Beat $8.518M Estimate.

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.67) per share which missed the analyst consensus estimate of $(1.64) by 1.83 percent. This is a 22.79 percent decrease over losses of $(1.36) per share from the

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

Cytokinetics Q4 Earnings Summary & Key Takeaways

Benzinga Insights

PRO
Cytokinetics Q4 EPS $(1.50) Misses $(1.45) Estimate, Sales $17.755M Beat $6.911M Estimate

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.50) per share which missed the analyst consensus estimate of $(1.45) by 3.45 percent. This is a 19.05 percent decrease over losses of $(1.26) per share from the

Benzinga Newsdesk

Earnings Scheduled For February 24, 2026

Benzinga Insights